Phathom Q3 Revenue Jumps 71% to $84.7M; Second Straight Quarter of Positive Operating Cash Flow
PHAT sits 33% above its 52-week low of $5.015.
Summary
Phathom reported Q3 2026 revenue of $84.7M (up 71% year over year), a near-breakeven operating loss, and positive operating cash flow for a second straight quarter, while reaffirming 2026 guidance and saying it needs no new debt or equity financing.
Key Events · Earnings and Guidance · PHAT
-
Q3 Revenue Up 71% to $84.7M
Net revenues rose $35.2M year over year from $49.5M and 14% sequentially from Q2 2026, with roughly 380,000 VOQUEZNA prescriptions filled in the quarter.
-
Near-Breakeven Quarter, Cash Flow Positive
Operating loss narrowed to $85 thousand from $15.3M a year ago; non-GAAP adjusted net income was $3.0M versus a $11.2M adjusted loss in Q3 2025, and operating cash flow was positive for a second consecutive quarter.
-
2026 Guidance Reaffirmed
Full-year 2026 net revenue guidance held at $310-325M with non-GAAP operating expenses of $235-245M; cash of $184.6M plus expected operating cash flow is stated to cover all debt obligations without new debt or equity.
-
Exclusivity Fight Enters Next Phase
The D.C. District Court granted Phathom's motion to intervene in BDR's suit against the FDA on October 26, 2026; the FDA comment docket closes November 23, 2026, with NCE exclusivity currently running to May 3, 2032.
Analysis · PHAT · Life Sciences
The commercial ramp is now self-funding: revenue of $84.7M rose 71% year over year and 14% sequentially, operating loss shrank to just $85 thousand from $15.3M a year ago, and the company generated positive operating cash flow for a second consecutive quarter. Management reaffirmed full-year 2026 revenue guidance of $310-325M and explicitly said cash on hand plus expected operating cash flow covers all outstanding debt obligations without new debt or equity — removing the dilution overhang that usually hangs over a company with a $347.6M stockholders' deficit. The main swing factor remains the BDR litigation over VOQUEZNA's NCE exclusivity through May 3, 2032; Phathom was granted intervention on October 26, 2026, and the FDA comment docket closes November 23, 2026. Next hard data point is EoE Phase 2 topline in Q4 2026.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PHAT was trading at $6.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $508.1M. The 52-week trading range was $5.02 to $18.31. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.